Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Yeast cell factory for mRNA bioproduction

Project description

Yeast-based bioproduction of RNA therapeutics

Ribonucleic acid (RNA) molecules are gaining momentum for the treatment of various conditions including in the generation of antiviral vaccines. However, RNA production relies on costly in vitro transcription methods. The EU-funded Yscript project proposes an alternative method for production of messenger RNA (mRNA) molecules, using yeast. Given the similarity in the structure between yeast and human mRNA, researchers will set up a technology for producing, isolating and purifying mRNA in yeast cells. This bioproduction platform will guarantee high purity and stability of target mRNA molecules – at a fraction of the cost. Importantly, it will lay the foundation for advancing the use of RNA therapeutics in medicine.

Objective

Messenger RNA (mRNA) vaccines have become a game-changer in the fight against COVID-19, providing an exit strategy to the global crisis of our age. mRNA is now considered a promising biopharmaceutical for a vast array of medical applications. Currently, in vitro transcription (IVT) is the only available technology for mRNA production; however, it relies on a complex supply chain and costly purification process. Reliable large-scale IVT production is challenging and high production costs are an issue for low-income countries, and this will be even more critical for clinical mRNA applications requiring high doses. Yscript’s groundbreaking nature lies in the generation of a specific mRNA bioproduction process in yeast, integrating innovative extraction and purification processes, representing a complete shift of paradigm compared to IVT production and a revolutionary new use of yeast. Although yeast possesses a similar mature mRNA structure as humans and is recognized as safe for pharmaceutical production, mRNA bioproduction and isolation have never been attempted. Yscript will provide groundbreaking technological improvements by: i) decreasing the mRNA production supply chain; ii) increasing the purity yield of long mRNA by avoiding premature termination occurring during IVT; and iii) guarantying mRNA stability through integrated extraction-purification processes. This will ensure the generation of high-quality mRNA therapeutics, while streamlining production and reducing costs. Yscript brings together world-class expertise in molecular biology, biophysics, biotechnology, chemistry, chemical engineering, mRNA therapeutics, yeast Ty biology, bioproduction and purification processes. The project will significantly advance the current state of the art of mRNA manufacturing. Yscript will foster citizens’ well-being and health, while decreasing economic and social disparities associated with biopharmaceutical-based therapies, in which mRNA is nowadays a key element.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2021-PATHFINDEROPEN-01

See all projects funded under this call

Coordinator

UNIVERSITE D'ORLEANS
Net EU contribution
€ 373 189,25
Address
CHATEAU DE LA SOURCE
45067 Orleans Cedex 2
France
Region
Centre — Val de Loire Centre — Val de Loire Loiret
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 373 189,25

Participants (10)